Novartis’ Reprieve On Generic Diovan Continues, Tasigna Makes Inroads
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss drug maker’s executives wouldn’t discuss overall progress of its strategic review under new chairman Joerg Reinhardt on its third quarter conference call, but highlighted the growth of several of its key pharmaceutical products and raised its outlook for 2013 in light of Diovan’s strength.